Brian Gallagher
Chairman chez EFFECTOR THERAPEUTICS, INC.
Fortune : 17 268 $ au 31/03/2024
Profil
Brian M.
Gallagher's current job(s) include Chairman at eFFECTOR Therapeutics, Inc., Director at eFFECTOR Therapeutics Operations, Inc., Director at Nimbus Apollo, Inc., and Director at Q32 Bio, Inc. Dr. Gallagher's former job(s) include Director at CalciMedica, Inc. (US) from 2013 to 2018, Director at Aileron Therapeutics, Inc. from 2010 to 2018, Director at Dicerna Pharmaceuticals, Inc., Director at SpringLeaf Therapeutics, Inc., Director at Nimbus Therapeutics LLC from 2011 to 2018, Independent Director at Translate Bio, Inc. from 2011 to 2019, Director at River Vision Development Corp.
from 2012 to 2017, Director at Navitor Pharmaceuticals, Inc. from 2014 to 2018, Director at Constellation Pharmaceuticals, Inc., Group Leader at Eisai Co., Ltd., Principal at Sirtris Pharmaceuticals, Inc., Principal at Alantos Pharmaceuticals Holding, Inc., and Partner at GSK Equity Investments Ltd.
from 2010 to 2018.
Dr. Gallagher was also a Partner at Abingworth Management, Inc. from 2018 to 2022.
Dr. Gallagher's education history includes an undergraduate degree from the University of Massachusetts and graduate and doctorate degrees from the University of Michigan.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 29/02/2024 | 1 200 ( 0,03% ) | 17 268 $ | 31/03/2024 |
Postes actifs de Brian Gallagher
| Sociétés | Poste | Début |
|---|---|---|
| EFFECTOR THERAPEUTICS, INC. | Chairman | 01/08/2021 |
eFFECTOR Therapeutics Operations, Inc.
 eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Director/Board Member | - |
Nimbus Apollo, Inc.
 Nimbus Apollo, Inc. Pharmaceuticals: MajorHealth Technology Nimbus Apollo, Inc. provides drug discovery research services. The company is headquartered in Cambridge, MA. | Director/Board Member | - |
Q32 Bio, Inc.
 Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | Director/Board Member | - |
Anciens postes connus de Brian Gallagher
| Sociétés | Poste | Fin |
|---|---|---|
Abingworth Management, Inc.
 Abingworth Management, Inc. Investment ManagersFinance Abingworth Management, Inc. invests in life sciences and biomedical companies. The firm's investment in enables technologies, devices and instrumentation as well as companies developing products in therapeutic areas. The company was founded in 1973 and is headquartered in Menlo Park, CA. | Private Equity Investor | 01/01/2022 |
| TRANSLATE BIO, INC. | Director/Board Member | 01/01/2019 |
| AILERON THERAPEUTICS, INC. | Director/Board Member | 19/03/2018 |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Corporate Officer/Principal | 01/01/2018 |
CalciMedica, Inc. (US)
 CalciMedica, Inc. (US) BiotechnologyHealth Technology CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA. | Director/Board Member | 01/01/2018 |
Formation de Brian Gallagher
| University of Massachusetts | Undergraduate Degree |
| University of Michigan | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| EISAI CO., LTD. | Health Technology |
| AILERON THERAPEUTICS, INC. | Health Technology |
| EFFECTOR THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 15 |
|---|---|
Sirtris Pharmaceuticals, Inc.
 Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | Health Technology |
Alantos Pharmaceuticals Holding, Inc.
 Alantos Pharmaceuticals Holding, Inc. Pharmaceuticals: MajorHealth Technology Alantos Pharmaceuticals Holding, Inc. manufactures bio-pharmaceutical products. The firm develops small molecule compounds for inflammatory cytokine pathways. The company was founded in 1999 and is headquartered in Thousand Oaks, CA. | Health Technology |
CalciMedica, Inc. (US)
CalciMedica, Inc. (US) BiotechnologyHealth Technology CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA. | Health Technology |
Dicerna Pharmaceuticals, Inc.
 Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
SpringLeaf Therapeutics, Inc.
 SpringLeaf Therapeutics, Inc. Drugstore ChainsRetail Trade SpringLeaf Therapeutics, Inc. is creating innovative therapeutic modalities to address serious disease and elevate the quality of care for patients. SpringLeaf's technology is based on the convergence of materials science and medicine and is designed to enable and differentiate therapeutics. SpringLeaf was founded based on breakthrough science at MIT and is backed by leading investors including Excel Venture Management, Flybridge Capital Partners, North Bridge Venture Partners and SR One. | Retail Trade |
Nimbus Therapeutics LLC
 Nimbus Therapeutics LLC BiotechnologyHealth Technology Nimbus Therapeutics LLC provides drug discovery research services. It is a computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was founded by Bruce Lee Booth in 2009 and is headquartered in Cambridge, MA. | Health Technology |
Translate Bio, Inc.
 Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
River Vision Development Corp.
 River Vision Development Corp. BiotechnologyHealth Technology River Vision Development Corp. develops novel protein therapies. The firm provides therapy for the treatment of graves orbitopathy which is a condition in which an autoimmune response is mounted against tissues behind the eye, causing inflammation, tissue proliferation and excess production of extracellular matrix. The company was founded in 2011 and is headquartered in New York, NY. | Health Technology |
Navitor Pharmaceuticals, Inc.
 Navitor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Navitor Pharmaceuticals, Inc. develops medicine for age-related diseases. Its drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. The company was founded by Alan L. Crane, David Sabatini and David Goldfarb and is headquartered in Cambridge, MA. | Health Technology |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Finance |
Abingworth Management, Inc.
Abingworth Management, Inc. Investment ManagersFinance Abingworth Management, Inc. invests in life sciences and biomedical companies. The firm's investment in enables technologies, devices and instrumentation as well as companies developing products in therapeutic areas. The company was founded in 1973 and is headquartered in Menlo Park, CA. | Finance |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Commercial Services |
Nimbus Apollo, Inc.
Nimbus Apollo, Inc. Pharmaceuticals: MajorHealth Technology Nimbus Apollo, Inc. provides drug discovery research services. The company is headquartered in Cambridge, MA. | Health Technology |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | Health Technology |
